{"id":"W4385693606","doi":"10.2337/dc23-0492","title":"Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes","year":2023,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Heart, Lung, and Blood Institute; Genentech; Esperion Therapeutics; Silence Therapeutics; HLS Therapeutics; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Pfizer; Moderna; Regado Biosciences; Hebrew University of Jerusalem; Belvoir Media Group; Novo Nordisk; MyoKardia; Allergan; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amgen; St. Jude Medical; Kowa Company; Sanofi; American Heart Association; U.S. Department of Veterans Affairs","keywords":"Medicine; Dapagliflozin; Kidney disease; Internal medicine; Type 2 diabetes; Renal function; Glycated hemoglobin; TIMI; Myocardial infarction; Framingham Risk Score; Diabetes mellitus; Hazard ratio; Creatinine; Endocrinology; Disease; Percutaneous coronary intervention; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006657525,0.0006677388,0.0008198297,0.001144444,0.000271889,0.0009776354,0.0004735621,0.0005439415,0.0007426462],"category_scores_gemma":[0.01608749,0.0002150693,0.001213165,0.0009824239,0.0002250069,0.0005488468,0.0006942641,0.000885291,0.0001670179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003208906,"about_ca_system_score_gemma":0.0005205451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001150326,"about_ca_topic_score_gemma":0.001350581,"domain_scores_codex":[0.9973404,0.001441499,0.0002677082,0.0003055061,0.000548895,0.00009600112],"domain_scores_gemma":[0.9870401,0.00562058,0.005231532,0.0005468007,0.001009753,0.000551258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008594817,0.00003920737,0.9926493,0.00002511014,0.000417496,0.00002112581,0.00002329964,0.0006541635,0.00008067471,0.00002452961,0.0001370029,0.005068641],"study_design_scores_gemma":[0.0001850267,0.000763022,0.9788274,0.00003947814,0.0005598219,0.0002071406,0.00005154177,0.01853206,0.0003028079,0.0001638652,0.0003480409,0.00001990052],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957432,0.0009409115,0.001940769,0.0001812085,0.00001910206,0.00004717681,0.0005745114,0.00002422519,0.0005288245],"genre_scores_gemma":[0.9977778,0.0001447994,0.001444341,0.0000388973,0.00003223764,0.00003088802,0.0004275548,0.000002928947,0.0001005397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006657525,"threshold_uncertainty_score":0.03520876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005707628824073473,"score_gpt":0.2592585962387875,"score_spread":0.253550967414714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}